Kenvue Inc. (KVUE)

Market Cap	44.12B
Revenue (ttm)	15.46B
Net Income (ttm)	1.03B
Shares Out	1.91B
EPS (ttm)	0.54
PE Ratio	42.92
Forward PE	20.15
Dividend	$0.82 (3.55%)
Ex-Dividend Date	Feb 12, 2025

Volume	12,446,780
Open	23.40
Previous Close	23.37
Day's Range	22.98 - 23.47
52-Week Range	17.67 - 24.46
Beta	n/a
Analysts	Buy
Price Target	23.85 (+3.31%)
Earnings Date	May 6, 2025

About KVUE

Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• IPO Date: May 4, 2023
• Employees: 22,000
• Stock Exchange: NYSE
• Ticker Symbol: KVUE
• Website: https://www.kenvue.com

Financial Performance

In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.

Analyst Forecast

According to 14 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price forecast is $23.85, which is an increase of 3.31% from the latest price.

Price Target

$23.85

(3.31% upside)

Analyst Consensus: Buy